Page 86 - Read Online

Page 8 of 12 Lorenzin et al. J Transl Genet Genom 2019;3:5. I https://doi.org/10.20517/jtgg.2019.01

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in
metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.
3. Huggins ML. A new society for x-ray and electron diffraction research workers. Science 1941;93:489-90.
4. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha
(17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73.
5. Chan FC, Potter GA, Barrie SE, Haynes BP, Rowlands MG, et al. 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human
cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med
Chem 1996;39:3319-23.
6. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-
C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-71.
7. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. Development of a second-generation antiandrogen for treatment of advanced prostate
cancer. Science 2009;324:787-90.
8. Rubin MA, Demichelis F. The genomics of prostate cancer: a historic perspective. Cold Spring Harb Perspect Med 2018; doi: 10.1101/
cshperspect.a034942.
9. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-25.
10. Rubin MA, Girelli G, Demichelis F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol
2016;69:557-60.
11. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12
mutations in prostate cancer. Nat Genet 2012;44:685-9.
12. Gandellini P, Casiraghi N, Rancati T, Benelli M, Doldi V, et al. Core biopsies from prostate cancer patients in active surveillance protocols
harbor PTEN and MYC alterations. European Urology Oncology. Forthcoming 2019.
13. Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, et al. Appraising the relevance of DNA copy number loss and gain in prostate
cancer using whole genome DNA sequence data. PLoS Genet 2017;13:e1007001.
14. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, et al. Copy number alteration burden predicts prostate cancer relapse. Proc
Natl Acad Sci U S A 2014;111:11139-44.
15. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153:666-
77.
16. Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, et al. Genomic hallmarks of localized, non-indolent prostate cancer.
Nature 2017;541:359-64.
17. Jaratlerdsiri W, Chan EKF, Petersen DC, Yang C, Croucher PI, et al. Next generation mapping reveals novel large genomic rearrangements
in prostate cancer. Oncotarget 2017;8:23588-602.
18. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell
2018;174:758-69.e9.
19. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, et al. Integrative clinical genomics of advanced prostate cancer. Cell
2015;161:1215-28.
20. Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, et al. Integrative clinical genomics of metastatic cancer. Nature 2017;548:297-303.
21. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, et al. Sequencing of prostate cancers identifies new cancer genes, routes
of progression and drug targets. Nat Genet 2018;50:682-92.
22. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet
2018;50:645-51.
23. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer.